John Frederick De Groot

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

Inflammation and tumor progression: signaling pathways and targeted intervention

Combinations of Bevacizumab With Cancer Immunotherapy

Targeting apoptosis in cancer therapy

Broadening horizons: the role of ferroptosis in cancer

Macrophages as regulators of tumour immunity and immunotherapy

Enhancing Cancer Immunotherapy Via Activation of Innate Immunity

VEGF in Signaling and Disease: Beyond Discovery and Development

Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy

Copper induces cell death by targeting lipoylated TCA cycle proteins

N‐Carboxyanhydride Polymerization of Glycopolypeptides That Activate Antigen‐Presenting Cells through Dectin‐1 and Dectin‐2

Single agent ONC201 in adult recurrent H3 K27M-mutant glioma.

Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients.

A phase 2 study of orally administered PLX3397 in patients with recurrent glioblastoma.